Especially, the previously delineated interrelation of the Hippo pathway with PD-L1 expression level combined with the continuous activity in the field of pharmaceutic industry for direct Hippo therapeutic suppression creates a very promising field of research in the direction of generation of promising combination targeted therapeutic schemes, whose implementation can add even more options in the battle against cancer. This evidence concerns the gene CD274 and cancer.